Search

Your search keyword '"Uy, Geoffrey L."' showing total 12 results
Start Over Author "Uy, Geoffrey L." Journal haematologica
12 results on '"Uy, Geoffrey L."'

1. Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes

Author

Gruszczynska, Agata, primary, Maiti, Abhishek, additional, Miller, Christopher A., additional, Ramakrishnan, Sai Mukund, additional, Link, Daniel C., additional, Uy, Geoffrey L., additional, Petti, Allegra A., additional, Hayes, Kala, additional, DiNardo, Courtney D., additional, Ravandi, Farhad, additional, Ley, Timothy J., additional, Spencer, David H., additional, Gao, Feng, additional, Konopleva, Marina Y., additional, and Welch, John S., additional

Published
2024
Full Text
View/download PDF

2. Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy

Author

Ferraro, Francesca, primary, Gruszczynska, Agata, additional, Ruzinova, Marianna B., additional, Miller, Christopher A., additional, Percival, Mary Elizabeth, additional, Uy, Geoffrey L., additional, Pusic, Iskra, additional, Jacoby, Meagan A., additional, Christopher, Mathew J., additional, Kim, Miriam Y., additional, Westervelt, Peter, additional, Cashen, Amanda F., additional, Schroeder, Mark A., additional, DiPersio, John F., additional, Abboud, Camille N., additional, Wartman, Lukas D., additional, Gao, Feng, additional, Link, Daniel C., additional, Ley, Timothy J., additional, and Welch, John S., additional

Published
2022
Full Text
View/download PDF

3. A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

Author

Vasu, Sumithira, primary, Altman, Jessica K., additional, Uy, Geoffrey L., additional, Tallman, Martin S., additional, Gojo, Ivana, additional, Lozanski, Gerard, additional, Burkard, Ute, additional, Osswald, Annika, additional, James, Pamela, additional, Rüter, Björn, additional, and Blum, William, additional

Published
2021
Full Text
View/download PDF

4. Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia

Author

Papaioannou, Dimitrios, primary, Ozer, Hatice G., additional, Nicolet, Deedra, additional, Urs, Amog P., additional, Herold, Tobias, additional, Mrózek, Krzysztof, additional, Batcha, Aarif M.N., additional, Metzeler, Klaus H., additional, Yilmaz, Ayse S., additional, Volinia, Stefano, additional, Bill, Marius, additional, Kohlschmidt, Jessica, additional, Pietrzak, Maciej, additional, Walker, Christopher J., additional, Carroll, Andrew J., additional, Braess, Jan, additional, Powell, Bayard L., additional, Eisfeld, Ann-Kathrin, additional, Uy, Geoffrey L., additional, Wang, Eunice S., additional, Kolitz, Jonathan E., additional, Stone, Richard M., additional, Hiddemann, Wolfgang, additional, Byrd, John C., additional, Bloomfield, Clara D., additional, and Garzon, Ramiro, additional

Published
2021
Full Text
View/download PDF

5. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia

Author

Abboud, Ramzi, primary, Chendamarai, Ezhilarasi, additional, Rettig, Michael P., additional, Trinkaus, Kathryn M., additional, Riedell, Peter A., additional, Abboud, Camille N., additional, Ghobadi, Armin, additional, Pusic, Iskra, additional, Stockerl-Goldstein, Keith, additional, Schroeder, Mark A., additional, Vij, Ravi, additional, Westervelt, Peter, additional, DiPersio, John F., additional, and Uy, Geoffrey L., additional

Published
2019
Full Text
View/download PDF

6. Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia

Author

Papaioannou, Dimitrios, primary, Nicolet, Deedra, additional, Volinia, Stefano, additional, Mrózek, Krzysztof, additional, Yan, Pearlly, additional, Bundschuh, Ralf, additional, Carroll, Andrew J., additional, Kohlschmidt, Jessica, additional, Blum, William, additional, Powell, Bayard L., additional, Uy, Geoffrey L., additional, Kolitz, Jonathan E., additional, Wang, Eunice S., additional, Eisfeld, Ann-Kathrin, additional, Orwick, Shelley J., additional, Lucas, David M., additional, Caligiuri, Michael A., additional, Stone, Richard M., additional, Byrd, John C., additional, Garzon, Ramiro, additional, and Bloomfield, Clara D., additional

Published
2017
Full Text
View/download PDF

7. Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide

Author

Goldsmith, Scott R., primary, Slade, Michael, additional, DiPersio, John F., additional, Westervelt, Peter, additional, Lawrence, Steven J., additional, Uy, Geoffrey L., additional, Abboud, Camille N., additional, Vij, Ravi, additional, Schroeder, Mark A., additional, Fehniger, Todd A., additional, Dubberke, Erik R., additional, Trinkaus, Kathryn, additional, and Romee, Rizwan, additional

Published
2016
Full Text
View/download PDF

8. Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.

Author

Gruszczynska A, Maiti A, Miller CA, Ramakrishnan SM, Link DC, Uy GL, Petti AA, Hayes K, DiNardo CD, Ravandi F, Ley TJ, Spencer DH, Gao F, Konopleva MY, and Welch JS

Subjects
Humans, Male, Aged, Female, Treatment Outcome, Middle Aged, Adult, Decitabine therapeutic use, Decitabine pharmacology, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Myelodysplastic Syndromes drug therapy, Myelodysplastic Syndromes genetics, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, Sulfonamides therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use
Published
2024
Full Text
View/download PDF

9. Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.

Author

Papaioannou D, Ozer HG, Nicolet D, Urs AP, Herold T, Mrózek K, Batcha AMN, Metzeler KH, Yilmaz AS, Volinia S, Bill M, Kohlschmidt J, Pietrzak M, Walker CJ, Carroll AJ, Braess J, Powell BL, Eisfeld AK, Uy GL, Wang ES, Kolitz JE, Stone RM, Hiddemann W, Byrd JC, Bloomfield CD, and Garzon R

Subjects
Adult, Cytosine, Humans, Middle Aged, Mutation, Prognosis, Thymidine, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute metabolism, RNA, Long Noncoding genetics, Transcriptome
Abstract

Expression levels of long non-coding RNA (lncRNA) have been shown to associate with clinical outcome of patients with cytogenetically normal acute myeloid leukemia (CN-AML). However, the frequency and clinical significance of genetic variants in the nucleotide sequences of lncRNA in AML patients is unknown. Herein, we analyzed total RNA sequencing data of 377 younger adults (aged <60 years) with CN-AML, who were comprehensively characterized with regard to clinical outcome. We used available genomic databases and stringent filters to annotate genetic variants unequivocally located in the non-coding transcriptome of AML patients. We detected 981 variants, which are recurrently present in lncRNA that are expressed in leukemic blasts. Among these variants, we identified a cytosine-to-thymidine variant in the lncRNA RP5-1074L1.4 and a cytosine-to-thymidine variant in the lncRNA SNHG15, which independently associated with longer survival of CN-AML patients. The presence of the SNHG15 cytosine-to-thymidine variant was also found to associate with better outcome in an independent dataset of CN-AML patients, despite differences in treatment protocols and RNA sequencing techniques. In order to gain biological insights, we cloned and overexpressed both wild-type and variant versions of the SNHG15 lncRNA. In keeping with its negative prognostic impact, overexpression of the wild-type SNHG15 associated with higher proliferation rate of leukemic blasts when compared with the cytosine-to-thymidine variant. We conclude that recurrent genetic variants of lncRNA that are expressed in the leukemic blasts of CN-AML patients have prognostic and potential biological significance.

Published
2022
Full Text
View/download PDF

11. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.

Author

Abboud R, Chendamarai E, Rettig MP, Trinkaus KM, Riedell PA, Abboud CN, Ghobadi A, Pusic I, Stockerl-Goldstein K, Schroeder MA, Vij R, Westervelt P, DiPersio JF, and Uy GL

Subjects
Adult, Aged, Animals, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cytarabine therapeutic use, Female, Filgrastim therapeutic use, Humans, Hydrazines, Male, Mice, Inbred C57BL, Middle Aged, Remission Induction, Treatment Outcome, Triazoles, Young Adult, Cladribine therapeutic use, Leukemia, Myeloid, Acute drug therapy
Published
2020
Full Text
View/download PDF

12. The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma.

Author

Uy GL, Tomasson MH, Ruddell A, DiPersio JF, and Vij R

Subjects
Adult, Aged, Clofarabine, Female, Humans, Male, Middle Aged, Multiple Myeloma blood, Neoplasm Recurrence, Local blood, Neutropenia blood, Neutropenia chemically induced, Adenine Nucleotides administration & dosage, Adenine Nucleotides adverse effects, Arabinonucleosides administration & dosage, Arabinonucleosides adverse effects, Multiple Myeloma drug therapy, Neoplasm Recurrence, Local drug therapy
Abstract

Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m2/day on days 1-5 of a 28 day cycle. No objective evidence of anti-myeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results